5-Fluoroisatin – >98.0%(HPLC), high purity , CAS No.443-69-6

5-Fluoroisatin has been reported as the precursor of the Sunitinib (Sutent) drug. 5-Fluoroisatin has been approved by the Food and Drugs Administration (FDA) in 2006 for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST).
5-Fluoroisatin may be used as reaction-based probe for live-cell detection of peroxynitrite by 19F magnetic resonance spectroscopy;in non-invasive detection of peroxynitrite (ONOO(-)) formation in living lung epithelial cells stimulated with interferon-? (IFN-?);in the synthesis of bis-Schiff bases, via condensation with aromatic primary bis-amines in water suspension medium without using any organic solvent or acid catalyst;in the synthesis of 3-acetonyl-5-fluoro-3-hydroxyoxindole Reactant for preparation of:Spiro[indole-thiazolidinones] as biologically relevan synthesis scaffolds;Potential antimycobacterial agents;Inhibitors of c-Met kinase;Inhibitors of TAK1 kinase;Herpes simplex virus inhibitors;IKK? inhibitors; Inhibitors of vitiligo disease; Potential drug candidates with anti-HIV activity and anti-tubercular activity